As part of our monthly news service we would like to make you aware of the CML publications of the month. From the many papers published every month Professor Timothy Hughes has selected topical, interesting papers for your perusal that also include interesting publications on pediatric CML.

Read Professor Hughes' CML publications of the month: August 2025

Clinical CML papers

• Asciminib remained superior versus bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL
  Mauro MJ et al. Blood Adv, August 2025 – open access publication
• Venetoclax in combination with ponatinib for the treatment of asciminib-resistant chronic myeloid leukemia
  Curik N et al. Leukemia, August 2025 (epub ahead of print) – open access publication
• Tyrosine kinase inhibitor discontinuation and reinitiation patterns in CML patients in the US: Real-world experience
  Sarker J et al. Leuk Lymphoma, August 2025
• Treatment-free remission in chronic myeloid leukemia patients with accelerated phase or tyrosine kinase inhibitor therapy failure
  Yuan M et al. Br J Haematol, August 2025 (epub ahead of print) – open access publication
• Cardiovascular disease in patients with chronic myeloid leukemia: JACC: CardioOncology State-of-the-Art Review
  Aghel N and Lipton JH. JACC CardioOncol, August 2025 – open access publication
• Outcome of chronic myeloid leukemia patients not in deep molecular response: Results from the GIMEMA LabNet CML Network database
  Stagno F et al. Am J Hematol, August 2025 – open access publication
• Real-world outcomes in patients with Philadelphia-chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia treated with ponatinib – Final 6-year results from a Belgian registry
  Devos T et al. Hematology, August 2025 (epub ahead of print) – open access publication
• How I manage chronic myeloid leukemia during pregnancy
  Abruzzese E and Chelysheva E. Blood, August 2025 (epub ahead of print)
• Outcomes and patterns of relapse with ponatinib-based therapy in patients with chronic myeloid leukemia in blast phase
  Karrar O et al. Leuk Lymphoma, August 2025 (epub ahead of print)
• Indolent chronic myeloid leukemia – a historical dinosaur?
  Lipton JH. Leuk Lymphoma, August 2025 (epub ahead of print)
• Unusually indolent CML: Absence of complete cytogenetic response after 10 years of tyrosine kinase inhibitor therapy
  Shen Q et al. Clin Lymphoma Myeloma Leuk, August 2025
• Evaluating a predictive model of tyrosine kinase inhibitor therapy failure in a European-type cohort: A step towards population-specific tools
  Moinard S et al. Leukemia, August 2025 (epub ahead of print) – open access publication
• Asciminib in late-line CML treatment
  Sweet K and Pinilla-Ibarz J. Blood Adv, August 2025 – open access publication

Scientific CML papers

• Flow cytometric detection of BCR::ABL1 in T-lymphocytes in chronic myeloid leukemia
  Buic D et al. Pathology, August 2025 – open access publication
• T cell receptor mimic CAR T cells targeting cathepsin G signal peptide
  Yan J et al. Leukemia, August 2025

Pediatric CML papers

• Complications at diagnosis of pediatric chronic myeloid leukemia in chronic phase
  Roy Moulik N et al. Pediatr Blood Cancer, August 2025 (epub ahead of print) – open access publication

Read Professor Hughes' summaries of key CML publications

This series of paper summaries is an extension of Professor Tim Hughes' 'CML publications of the month' news service. These summaries, selected and curated by Professor Hughes, will be compiled and provided every three months, offering a comprehensive overview of key CML papers. This approach ensures that clinicians, researchers, and healthcare professionals stay up-to-date with important pivotal studies and emerging trends in CML research.

CML paper summary #5 - August 2025:

Favourable rates of cardiovascular events with stringent cardiovascular monitoring and a lowered dose of ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients failing or intolerant to first-line second-generation tyrosine kinase inhibitor treatment: Results of the prospective PONS Trial
Link to full paper: (Acta Haematol 2025 May 5:1-8)

This prospective phase 2 study published in Acta Haematol evaluated ponatinib at a lowered startingdose (30 mg daily) as a second-line treatment in chronic phase chronic myeloid leukemia (CP-CML) patients who were resistant or intolerant to a first-line second-generation TKI. 

Read more